{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:16:04Z","timestamp":1790072164239,"version":"4.0.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Invasive pneumococcal disease (IPD) remains a significant burden despite implementation of pneumococcal conjugate vaccines (PCVs) in childhood immunization programs.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To analyze IPD epidemiology in Canada following 7-valent pneumococcal conjugate vaccine (PCV7) and 13-valent PCV (PCV13) introductions and evaluate the potential outcomes associated with newer vaccines, such as PCV15, PCV20, and PCV21.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study included IPD isolates from children and adults with IPD across Canada from January 1, 2000, to December 31, 2019. Cases were identified through bacterial isolates sent to national reference laboratories. Data were analyzed from January 2022 to January 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Introduction of PCV7 and PCV13.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n IPD incidence rates and proportion analyses were calculated for serotypes belonging to PCV7, PCV13, PCV15, PCV20, and PCV21 using Statistics Canada population estimates. PCV7 and PCV13 impact was assessed using generalized linear piecewise quasi-Poisson regression models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 37\u202f921 IPD isolates were analyzed. Age data were available for 37\u202f591 isolates (17.9% children aged &amp;lt;18 years; 82.1% adults aged \u226518 years), and sex data for 35\u202f303 isolates (51.5% male; 41.6% female). Following PCV7 introduction, PCV7-specific serotype IPD rates decreased by 98.5%, from an incidence rate (IR) of 20.1 (95% CI, 17.8-22.6) in year 0 to 0.31 (95% CI, 1.0-0.5) in year 7 (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), in children younger than 5 years (direct cohort) and 76.3%, from an IR of 2.2 (95% CI, 1.6-3.0) in year 0 to (0.5; 95% CI, 0.3-0.9) in year 7, in individuals aged 10 years or older (indirect cohort), although the difference was not statistically significant (\n P<\/jats:italic>\n \u2009=\u2009.74). After PCV13 introduction, PCV13-only serotype IPD rates decreased by 90.6% in the direct cohort, from an IR of 10.3 (95% CI, 8.812.1) in year 0 to 1.0 (95% CI, 0.65-1.44) in year 9 (\n P<\/jats:italic>\n \u2009=\u2009.03), and 57.1% in the indirect cohort, from an IR of 3.8 (95% CI, 3.1 to 4.6) in year 0 to 1.6 (95% CI, 1.2 to 2.1) in year 9 (\n P<\/jats:italic>\n \u2009=\u2009.001). Vaccine serotypes 3, 4, and 19F persisted, with increases observed in adults aged 18 to 49 years and 50 to 64 years for serotypes 3 and 4, and in adults aged 65 years and older for serotype 19F. Serotype 19A cases declined after introduction of PCV13, with the highest incidence in adults aged 65 years and older. From 2015 to 2019, the potential serotype coverages by PCV15, PCV20, and PCV21 were estimated at 23% to 29%, 32% to 39%, and 36% to 49%, respectively, while nonvaccine types accounted for 45% to 52%.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cross-sectional study of IPD isolates in Canada found that despite initial IPD reductions following PCVs, IPD in Canada increased, driven by emerging nonvaccine types and persistence of some vaccine serotypes. Indirect protection was limited, particularly among older adults, highlighting the need for direct adult vaccination strategies. These findings suggest that while PCV15, PCV20, and PCV21 may improve serotype coverage, continued development of broader-spectrum vaccines is essential to further reduce IPD burden.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.6005","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:22Z","timestamp":1775746822000},"page":"e266005","source":"Crossref","is-referenced-by-count":2,"title":["Invasive Pneumococcal Disease Epidemiology and Conjugate Vaccines in Canada, 2000-2019"],"prefix":"10.1001","volume":"9","author":[{"given":"Bernice","family":"Ramos","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada"},{"name":"Vaccine Evaluation Center, B.C. Children\u2019s Hospital Research Institute, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirma Khatri","family":"Vadlamudi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada"},{"name":"Vaccine Evaluation Center, B.C. Children\u2019s Hospital Research Institute, Vancouver, Canada"},{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Golden","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Martin","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Brousseau","sequence":"additional","affiliation":[{"name":"Department of Social and Preventive Medicine, Universit\u00e9 Laval, Quebec City, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada"},{"name":"Vaccine Evaluation Center, B.C. Children\u2019s Hospital Research Institute, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Canadian Immunization Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"9","key":"zoi260208r1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1473-3099(24)00176-2","article-title":"Global, regional, and national incidence and mortality burden of non\u2013COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.","volume":"24","author":"Bender","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"zoi260208r2","doi-asserted-by":"publisher","first-page":"a010215","DOI":"10.1101\/cshperspect.a010215","article-title":"The pneumococcus: epidemiology, microbiology, and pathogenesis.","volume":"3","author":"Henriques-Normark","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"zoi260208r3","doi-asserted-by":"publisher","first-page":"e00937","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus.","volume":"11","author":"Ganaie","year":"2020","journal-title":"mBio"},{"issue":"ACS-2","key":"zoi260208r4","first-page":"1","article-title":"An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.","volume":"28","author":"National Advisory Committee on Immunization","year":"2002","journal-title":"Can Commun Dis Rep"},{"issue":"ACS-12","key":"zoi260208r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14745\/ccdr.v36i00a12","article-title":"Update on the use of conjugate pneumococcal vaccines in childhood: an advisory committee statement (ACS) National Advisory Committee on Immunization (NACI).","volume":"36","author":"Desai","year":"2010","journal-title":"Can Commun Dis Rep"},{"issue":"8","key":"zoi260208r7","first-page":"1361","article-title":"Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom.","volume":"221","author":"Kandasamy","year":"2020","journal-title":"J Infect Dis"},{"issue":"5","key":"zoi260208r8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.vaccine.2017.12.035","article-title":"Re-emergence of pneumococcal colonization by vaccine serotype 19F in persons aged =5 years after 13-valent pneumococcal conjugate vaccine introduction\u2014Alaska, 2008-2013.","volume":"36","author":"Gounder","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"zoi260208r9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3201\/eid1805.110235","article-title":"Epidemic of invasive pneumococcal disease, western Canada, 2005-2009.","volume":"18","author":"Tyrrell","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"22","key":"zoi260208r10","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","article-title":"Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature.","volume":"35","author":"Tsaban","year":"2017","journal-title":"Vaccine"},{"issue":"ACS-5","key":"zoi260208r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14745\/ccdr.v39i00a05","article-title":"Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).","volume":"39","author":"Quach-Thanh","year":"2013","journal-title":"Can Commun Dis Rep"},{"issue":"3","key":"zoi260208r16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cid\/ciy129","article-title":"Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study.","volume":"67","author":"Jayasinghe","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"29","key":"zoi260208r17","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SPIDNET observational multicentre study.","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"zoi260208r18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112337","article-title":"Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.","volume":"9","author":"Garc\u00eda Gabarrot","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"zoi260208r19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/microorganisms9040742","article-title":"Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10\/13: the Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.","volume":"9","author":"Deloria Knoll","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"zoi260208r20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/microorganisms9040738","article-title":"Serotype distribution of remaining pneumococcal meningitis in the mature PCV10\/13 period: findings from the PSERENADE Project.","volume":"9","author":"Garcia Quesada","year":"2021","journal-title":"Microorganisms"},{"issue":"38","key":"zoi260208r21","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1016\/j.vaccine.2023.08.001","article-title":"Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.","volume":"41","author":"Grant","year":"2023","journal-title":"Vaccine"},{"issue":"14","key":"zoi260208r22","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.vaccine.2021.02.026","article-title":"Invasive pneumococcal disease due to 22F and 33F in England: a tail of two serotypes.","volume":"39","author":"Amin-Chowdhury","year":"2021","journal-title":"Vaccine"},{"key":"zoi260208r23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3389\/fmicb.2020.00309","article-title":"Clinical relevance and molecular pathogenesis of the emerging serotypes 22F and 33F of Streptococcus pneumoniae in Spain.","volume":"11","author":"Sempere","year":"2020","journal-title":"Front Microbiol"},{"issue":"12","key":"zoi260208r24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1080\/13696998.2020.1840216","article-title":"Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.","volume":"23","author":"Hu","year":"2020","journal-title":"J Med Econ"},{"issue":"1","key":"zoi260208r25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","article-title":"Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.","volume":"21","author":"Ouldali","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi260208r26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/17843286.2022.2039865","article-title":"The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.","volume":"78","author":"Janssens","year":"2023","journal-title":"Acta Clin Belg"},{"issue":"6","key":"zoi260208r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287378","article-title":"Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination\u2014a longitudinal study over 10 years based on public surveillance data in the Nordics.","volume":"18","author":"Palmborg","year":"2023","journal-title":"PLoS One"},{"issue":"38","key":"zoi260208r28","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1016\/j.vaccine.2019.09.065","article-title":"Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes.","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"issue":"38","key":"zoi260208r30","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1016\/j.vaccine.2023.07.049","article-title":"Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.","volume":"41","author":"Deceuninck","year":"2023","journal-title":"Vaccine"},{"issue":"1-2","key":"zoi260208r31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14745\/ccdr.v50i12a04","article-title":"PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity?","volume":"50","author":"De Wals","year":"2024","journal-title":"Can Commun Dis Rep"},{"issue":"7","key":"zoi260208r32","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3201\/eid2707.204403","article-title":"Whole-genome analysis of Streptococcus pneumoniae serotype 4 causing outbreak of invasive pneumococcal disease, Alberta, Canada.","volume":"27","author":"Kellner","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"zoi260208r33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico.","volume":"223","author":"Beall","year":"2021","journal-title":"J Infect Dis"},{"key":"zoi260208r6","unstructured":"Government of Canada. Vaccination coverage goals and vaccine preventable disease reduction targets by 2025. Modified August 16, 2022. Accessed February 26, 2026. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization-vaccine-priorities\/national-immunization-strategy\/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html"},{"key":"zoi260208r11","unstructured":"Public Health Agency of Canada. Pneumococcal vaccines: Canadian immunization guide. Modified September 10, 2024. Accessed January 6, 2025. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-16-pneumococcal-vaccine.html"},{"key":"zoi260208r12","unstructured":"Public Health Agency of Canada. National laboratory surveillance of invasive streptococcal disease in Canada\u2014annual summary 2014. Accessed May 21, 2024. https:\/\/www.canada.ca\/content\/dam\/canada\/health-canada\/migration\/healthy-canadians\/publications\/drugs-products-medicaments-produits\/2014-streptococcus\/alt\/surveillance-streptococca-eng.pdf"},{"key":"zoi260208r13","unstructured":"Public Health Agency of Canada. National laboratory surveillance of invasive streptococcal disease in Canada\u2014annual summary 2019. Accessed May 21, 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/drugs-health-products\/national-laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2019.html"},{"key":"zoi260208r14","unstructured":"Statistics Canada. Table 18-10-0005-01 population estimates on July1, by age and gender. Accessed January 6, 2025. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501"},{"key":"zoi260208r29","unstructured":"Public Health Agency of Canada. Vaccine uptake in Canadian adults: highlights from the 2020-2021 Seasonal Influenza Vaccination Coverage Survey. Published online 2022. Accessed June 13, 2025. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization-vaccines\/vaccination-coverage\/highlights-2020-2021-seasonal-influenza-survey\/full-report.html"},{"key":"zoi260208r34","unstructured":"Government of Canada. Publications: diseases and conditions. Accessed June 13, 2025. https:\/\/www.canada.ca\/en\/services\/health\/publications\/diseases-conditions.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847554\/ramos_2026_oi_260208_1775145199.80717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:24Z","timestamp":1775746824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6005","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}